Healthcare
Opus Genetics, Inc.(IRD)
Live Price
Offline$4.07
+0.25% today
1Y Change
+319.59%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $360.00M
- Revenue Growth
- +29.1%
- EPS Growth
- +62.8%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Opus Genetics, Inc. (IRD) is a Healthcare stock with a market cap of $360.00M and listed on NASDAQ. The stock last traded around $4.07 and up 319.6% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +29.1%, EPS growth of +62.8%, a dividend yield of 0.0%. What stands out right now is revenue +29.1%, EPS +62.8%, free cash flow -37.8% with operating margin -271.9% and ROIC -90.9%. Valuation already assumes a fairly strong business story at price/sales 25.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IRD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+29.1% vs +7.6% peer median
Operating Margin
Below sector median
-271.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +29.1% and EPS at +62.8%, with operating margin around -271.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -0.7% | +1.6% | โ |
2026 Mar 10, 2026 | -27.3% | +3.3% | -1.0% | +6.2% |
2025 Nov 12, 2025 | +14.3% | -3.6% | -3.1% | +27.1% |
Benchmark Edge
IRD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IRD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IRD Max Drawdown
-32.35%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IRD and SPY.
Company Overview
Opus Genetics, Inc.
NASDAQ Global Market
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
- Leadership
- George Magrath
- IPO Date
- Jan 19, 2015
- Employees
- 18
- Street Address
- 37000 Grand River Avenue
- Mailing
- Durham, MI, 48335
- Region
- Durham, MI, US
- Reporting Currency
- USD
- Investor Line
- 248 957 9024
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 25.5
- Price/Book
- 205.7
Growth
- Revenue
- +29.1%
- EPS
- +62.8%
- Free Cash Flow
- -37.8%
Profitability
- Gross Margin
- 57.4%
- Operating Margin
- -271.9%
- Net Margin
- -349.3%
- ROE
- -452.3%
- ROIC
- -90.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 6.43
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.